EQL PHARMA AB (7JK) — Defensive Interval Ratio
EQL PHARMA AB (7JK) has a Defensive Interval Ratio of 161 days as of March 2026. Defensive assets of €92.74 Million (cash €-, short-term investments €-, receivables €92.74 Million) cover 161 days of daily cash needs of €575.97K/day.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
EQL PHARMA AB Defensive Interval Ratio (2022–2026)
This chart shows how EQL PHARMA AB's Defensive Interval Ratio has evolved across 5 annual periods from 2022 to 2026. As of March 2026, the ratio stands at 161 days, meaning defensive assets of €92.74 Million can fund 161 days of operations without new revenue. For the complete balance sheet picture, see 7JK asset base.
Annual Defensive Interval Ratio for EQL PHARMA AB (2022–2026)
The table below presents the year-by-year Defensive Interval Ratio for EQL PHARMA AB from 2022 to 2026, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. See working capital to net assets of EQL PHARMA AB to evaluate short-term liquidity relative to the company's equity base.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2026 | 161 days | €92.74 Million | €575.98K/day | €- | €- | ▼ -47 days |
| 2025 | 208 days | €125.68 Million | €605.53K/day | €- | €- | ▲ +76 days |
| 2024 | 131 days | €58.34 Million | €443.97K/day | €- | €- | ▼ -30 days |
| 2023 | 161 days | €51.70 Million | €321.05K/day | €- | €- | ▲ +35 days |
| 2022 | 126 days | €34.10 Million | €270.57K/day | €- | €- | — |